logo negro baker tilly
Contact

biotechnology funding

biotechnology funding

We are together in each step
Array ( [0] => WP_Term Object ( [term_id] => 588 [name] => biotech-company-purchase [slug] => biotech-company-buying [term_group] => 0 [term_taxonomy_id] => 588 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 1 [filter] => raw ) [1] => WP_Term Object ( [term_id] => 260 [name] => financing-biotechnology [slug] => financiacion-biotecnologia [term_group] => 0 [term_taxonomy_id] => 260 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 5 [filter] => raw ) [2] => WP_Term Object ( [term_id] => 589 [name] => grifols [slug] => grifols [term_group] => 0 [term_taxonomy_id] => 589 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 2 [filter] => raw ) [3] => WP_Term Object ( [term_id] => 249 [name] => investment-in-biotechnology [slug] => investment-in-biotechnology [term_group] => 0 [term_taxonomy_id] => 249 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 4 [filter] => raw ) [4] => WP_Term Object ( [term_id] => 590 [name] => novartis [slug] => novartis [term_group] => 0 [term_taxonomy_id] => 590 [taxonomy] => post_tag [description] => [parent] => 0 [count] => 1 [filter] => raw ) )
Spanish biotech firm wins backing from international investors
According to the OECD, Spain is in the top 10 countries with the highest development of the biotechnology sector. Although this [...]
read more >>
Oryzon genomics floats on the MAB
Oryzon Genomics is listed on the MAB, reinforcing the biotech market, which is the largest listed on the MAB. From [...]
read more >>
France's Synerlab buys Alcalá Pharma
If a week ago we told you that Spanish biotechs were coming out on the MAB, this week it is the turn of Spanish biotechs [...].
read more >>
October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte
In the second half of October we have witnessed that two Spanish companies focused on providing solutions for the [...]
read more >>
Minoryx and Sanifit receive investment from Caixa Capital Risk to fight against rare diseases.
The biotechnology sector in general and the rare disease sector in particular has attracted the interest of Caixa Capit [...]
read more >>
crossmenuchevron-down